Ovarian Cancer Treatment Platinum-sensitive Relapse - Cohort Study (PROSPECTYON)

ARCAGY/ GINECO GROUP

Status: Completed

Conditions: Ovarian Cancer

Treatments: Drug: Yondelis®-Caelyx®

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT02163720

PROSPECTYON (GINECO-OV229)

Details and patient eligibility

About

The French cooperative group GINECO proposes to implement an observational study to describe a real situation, in daily practice tolerance and methods of administration of trabectedin (Yondelis®)-Pegylated liposomal doxorubicin(Caelyx)®, in ovarian platinum sensitive cancer relapse.

Full description

Population : Patients aged 18 years and older with an epithelial ovarian cancer, fallopian tube or primary peritoneal with platinum-sensitive recurrent witch it was decided to initiate a treatment with trabectedin (Yondelis®)-Pegylated liposomal doxorubicin(Caelyx)®.

Enrollment: 101 patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients aged 18 years and over,
• Patients with an epithelial ovarian cancer, fallopian tube or peritoneal who will receive Yondelis®-Caelyx® in relapse platinum-sensitive
• Patients should be informed of the study orally and should not have any objection their data to be processed

Exclusion criteria

• Patient participation in a clinical trial
• Patient non-affiliated to a social security scheme.

Trial design

101 participants in 1 patient group

Yondelis®-Caelyx®-relapse ovarian cancer

Description:

Yondelis®-Caelyx®-relapse ovarian cancer

Treatment:

Drug: Yondelis®-Caelyx®